Overall survival
| Demographic . | Event-free survival (95% CI), mo . | Overall survival (95% CI), mo . | P* . |
|---|---|---|---|
| All patients (N = 119) | 10 (9-15) | 14 (12-NR) | — |
| Spliceosome (n = 39) | 10 (6-NR) | 35 (13-NR) | .58 |
| ELN risk group | |||
| Favorable | NR (3-NA) | NR (3-NA) | .48 |
| Intermediate | 10 (8-NA) | NR (13-NA) | .97 |
| Adverse | 7 (3-NA) | 14 (5-NA) | .29 |
| Cytogenetic group | |||
| Diploid | NR (10-NA) | NR (−) | .57 |
| Other intermediate | 17 (9-NA) | 35 (13-NA) | .40 |
| Complex/adverse | 3 (2-NA) | 5 (3-NA) | .29 |
| AML type | |||
| De novo AML | 18 (8-NA) | NR (−) | .35 |
| Secondary AML | 7 (6-NA) | 10 (6-NA) | .80 |
| Therapy-related AML | 6 (5-NA) | 8 (6-NA) | .69 |
| Wild-type (n = 80) | 11 (9-19) | 14 (10-NA) | |
| ELN risk group | |||
| Favorable | 31 (13-NA) | NR (17-NA) | — |
| Intermediate | 32 (7-NA) | NR (12-NA) | — |
| Adverse | 9 (5.0-NA) | 10 (8-18) | — |
| Cytogenetic group | |||
| Diploid | 31 (20-NA) | NR (−) | — |
| Intermediate | 11 (7-NA) | 19 (9-NA) | — |
| Complex/adverse | 5 (5-10) | 9 (6-12) | — |
| AML type | |||
| De novo AML | 19 (11-NA) | 22 (14-NA) | — |
| Secondary AML | 5 (3.-NA) | 9 (6-NA) | — |
| Therapy-related AML | 6 (5.0-10) | 10 (5-NA) | — |
| Demographic . | Event-free survival (95% CI), mo . | Overall survival (95% CI), mo . | P* . |
|---|---|---|---|
| All patients (N = 119) | 10 (9-15) | 14 (12-NR) | — |
| Spliceosome (n = 39) | 10 (6-NR) | 35 (13-NR) | .58 |
| ELN risk group | |||
| Favorable | NR (3-NA) | NR (3-NA) | .48 |
| Intermediate | 10 (8-NA) | NR (13-NA) | .97 |
| Adverse | 7 (3-NA) | 14 (5-NA) | .29 |
| Cytogenetic group | |||
| Diploid | NR (10-NA) | NR (−) | .57 |
| Other intermediate | 17 (9-NA) | 35 (13-NA) | .40 |
| Complex/adverse | 3 (2-NA) | 5 (3-NA) | .29 |
| AML type | |||
| De novo AML | 18 (8-NA) | NR (−) | .35 |
| Secondary AML | 7 (6-NA) | 10 (6-NA) | .80 |
| Therapy-related AML | 6 (5-NA) | 8 (6-NA) | .69 |
| Wild-type (n = 80) | 11 (9-19) | 14 (10-NA) | |
| ELN risk group | |||
| Favorable | 31 (13-NA) | NR (17-NA) | — |
| Intermediate | 32 (7-NA) | NR (12-NA) | — |
| Adverse | 9 (5.0-NA) | 10 (8-18) | — |
| Cytogenetic group | |||
| Diploid | 31 (20-NA) | NR (−) | — |
| Intermediate | 11 (7-NA) | 19 (9-NA) | — |
| Complex/adverse | 5 (5-10) | 9 (6-12) | — |
| AML type | |||
| De novo AML | 19 (11-NA) | 22 (14-NA) | — |
| Secondary AML | 5 (3.-NA) | 9 (6-NA) | — |
| Therapy-related AML | 6 (5.0-10) | 10 (5-NA) | — |
NA, not available.
P value presented is comparison between spliceosome and wild-type cohorts for the respective demographic.